Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin Chemoradiotherapy +/- Capecitabine in Local Advanced Nasopharyngeal Carcinoma
NCT02973386Phase 3Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2017
- Primary completion
- Oct 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of capecitabine in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Distant metastasis-free survival at 5 years. Started Jan 2017; status: completed.
02
Drugs
capecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02973386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973386.